Literature DB >> 6617075

Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation.

B Mellström, L Bertilsson, Y C Lou, J Säwe, F Sjöqvist.   

Abstract

Amitriptyline AT demethylation to nortriptyline NT was determined in nine healthy subjects who had been phenotyped with respect to debrisoquine D hydroxylation capacity. AT demethylation was calculated from the ratio between the plasma AUCs of NT after single oral doses of AT and NT. Plasma clearance of AT by demethylation did not correlate with the ratio between D and 4-hydroxy-D in urine (rs = -0.55).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617075     DOI: 10.1038/clpt.1983.207

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 2.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

3.  Metabolism of amineptine in rat, dog and man.

Authors:  L Grislain; P Gelé; N Bromet; W Luijten; J P Volland; E Mocaer; A Kamoun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

4.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Discrepancies between pharmacokinetic studies of amitriptyline.

Authors:  P Schulz; P Dick; T F Blaschke; L Hollister
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  Sparteine oxidation polymorphism in Greenlanders living in Denmark.

Authors:  K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

8.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

10.  Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.

Authors:  K K Nielsen; K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.